FISCAL YEAR 2011 ANNUAL REVIEW OF OCULAR ALLERGY PRODUCTS

OKLAHOMA HEALTH CARE AUTHORITY

MARCH 2012

CURRENT PRIOR AUTHORIZATION OF OCULAR ALLERGY MEDICATIONS

Tier 2 authorization criteria:

1. FDA approved diagnosis
2. A trial of one Tier 1 product for a minimum of two weeks in the last 30 days that did not yield adequate relief of symptoms or resulted in intolerable adverse effects
3. Contraindication to lower tiered medications

Tier 3 authorization criteria:

1. FDA approved diagnosis
2. Recent trials of one Tier 1 product and all available Tier 2 medications for a minimum of two weeks each that did not yield adequate relief of symptoms or resulted in intolerable adverse effects
3. Contraindication to lower tiered medications

Tier 1	Tier 2	Tier 3
cromolyn (Crolom®) ketotifen (Alaway®,Zaditor OTC®)	olopatadine (Patanol®)*	nedocromil (Alocril®) pemirolast (Alamast®) emedastine (Emadine®) loteprednol (Alrex®) olopatadine (Pataday®) lodoxamide (Alomide®) epinastine (Elestat®) azelastine (Optivar®) bepotastine besilate (Bepreve™) alcaftadine (Lastacaft™)

*Supplemental rebate agreement

TRENDS IN UTILIZATION

Comparison of Fiscal Years 2010 & 2011

Fiscal Year	Members	Claims	Paid	Paid/Claim	Per-Diem	Units	Days
2010	6,004	8,445	$765,949.40	$90.70	$3.00	43,975	211,208
2011	4,640	6,957	$540,154.54	$77.64	$2.55	39,474	255,110
% change	**-22.7%**	**-17.6%**	**-29.5%**	**-14.4%**	**-15.0%**	**-10.2%**	**+20.8%**
change	**-1,364**	**-1,488**	**-$225,794.86**	**-$13.06**	**-$0.45**	**+7,400**	**+43,902**

Member Demographics of Members Utilizing Ocular Allergy Products in FY2011



Member Demographics Highlighting Less than 20 Years of Age



Top 10 Prescribers of Ocular Allergy Products by Number of Claims in FY2011



Prior Authorizations of Ocular Allergy Products in FY2011

For FY11 there were a total of 931 manual prior authorizations submitted for this category. Point-of-Sale (POS) systems are in place to determine appropriate step therapy and issue automatic approval when appropriate.



RECOMMENDATIONS

The College of Pharmacy does not recommend any changes to the current criteria.